

**Public**

## Environmental and Social Data Sheet

### Overview

Project Name:	NEWRON (EGFF)
Project Number:	2017-0788
Country:	Italy
Project Description:	Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system. The company is operational and already has one drug on the market (Xadago). The investment program consists of the discovery, pre-clinical and clinical development of a portfolio of assets, addressing different therapeutic areas focusing on underserved neurological conditions. The pharmaceutical assets are at various developmental stages.
EIA required:	no
Project included in Carbon Footprint Exercise <sup>1</sup> :	no
(details for projects included are provided in section: "EIB Carbon Footprint Exercise")	

### Environmental and Social Assessment

#### Environmental Assessment

The promoter's investments that are to be financed concern research, development and innovation activities that will be in the pharmaceutical and biotechnology sectors, enabling the company to advance its portfolio of promising and diverse drug-candidates along the drug-development value chain. The project's activities are not listed in any of the annexes of the EU Directive 2011/92/EU as amended by 2014/52/EU. Furthermore, the project will be carried out in existing facilities already authorised for similar activities and volumes. Therefore, an Environmental Impact Assessment (EIA) is not required.

The promoter's R&D practices are in compliance with relevant national and EU regulations (directives 2001/83/EC, 2005/28/EC, 2001/20/EC and Good Clinical Practice, as applicable) and the promoter maintains adequate internal procedures and management practices.

#### Social Assessment, where applicable

---

<sup>1</sup> Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: above 100,000 tons CO<sub>2</sub>e/year absolute (gross) or 20,000 tons CO<sub>2</sub>e/year relative (net) – both increases and savings.

Luxembourg, 24.07.2018

The project, if successful, is expected to lead to important social benefits stemming from its focus on the development of novel targeted therapies to address diseases linked with high-unmet medical and social needs.

Through the R&D activities and investments, the promoter expects to sustain and even increase its current level of highly-skilled personnel, while contributing to reinforce European scientific innovation and knowledge base, hence fostering and nurturing the vital research community.

### **Conclusions and Recommendations**

The project can be classified as acceptable with positive or no residual environmental impact. Moreover, if successful the project presents potentially high health and social benefits for the wider society. The project is therefore considered acceptable for EIB financing.

PJ/SQM/ECSO DD.MM.YYYY